RT Journal Article
T1 Effects of Virgin Olive Oils Differing in Their Bioactive Compound Contents on Metabolic Syndrome and Endothelial Functional Risk Biomarkers in Healthy Adults: A Randomized Double-Blind Controlled Trial.
A1 Sanchez-Rodriguez, Estefania
A1 Lima-Cabello, Elena
A1 Biel-Glesson, Sara
A1 Fernandez-Navarro, Jose R
A1 Calleja, Miguel A
A1 Roca, Maria
A1 Espejo-Calvo, Juan A
A1 Gil-Extremera, Blas
A1 Soria-Florido, Maria
A1 de la Torre, Rafael
A1 Fito, Montserrat
A1 Covas, Maria-Isabel
A1 Alche, Juan de Dios
A1 Martinez de Victoria, Emilio
A1 Gil, Angel
A1 Mesa, Maria D
K1 cardiovascular diseases
K1 endothelial function
K1 maslinic acid
K1 metabolic syndrome
K1 oleanolic acid
K1 olive oil
K1 olive oil polyphenols
K1 phenolic compounds
K1 triterpenes
K1 virgin olive oil
AB The aim of this study was to evaluate the effect of virgin olive oils (VOOs) enriched with phenolic compounds and triterpenes on metabolic syndrome and endothelial function biomarkers in healthy adults. The trial was a three-week randomized, crossover, controlled, double-blind, intervention study involving 58 subjects supplemented with a daily dose (30 mL) of three oils: (1) a VOO (124 ppm of phenolic compounds and 86 ppm of triterpenes); (2) an optimized VOO (OVOO) (490 ppm of phenolic compounds and 86 ppm of triterpenes); and (3) a functional olive oil (FOO) high in phenolic compounds (487 ppm) and enriched with triterpenes (389 ppm). Metabolic syndrome and endothelial function biomarkers were determined in vivo and ex vivo. Plasma high density lipoprotein cholesterol (HDLc) increased after the OVOO intake. Plasma endothelin-1 levels decreased after the intake of the three olive oils, and in blood cell cultures challenged. Daily intake of VOO enriched in phenolic compounds improved plasma HDLc, although no differences were found at the end of the three interventions, while VOO with at least 124 ppm of phenolic compounds, regardless of the triterpenes content improved the systemic endothelin-1 levels in vivo and ex vivo. No effect of triterpenes was observed after three weeks of interventions. Results need to be confirmed in subjects with metabolic syndrome and impaired endothelial function (Clinical Trials number NCT02520739).
YR 2018
FD 2018-05-16
LK http://hdl.handle.net/10668/12479
UL http://hdl.handle.net/10668/12479
LA en
DS RISalud
RD Apr 13, 2025